文献速递乳腺癌放疗

70岁以上低危早期乳腺癌:单纯放疗对比单纯内分泌治疗的微模拟研究

Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-06-15

该微模拟研究构建患者水平马尔可夫模型,比较70岁以上低危激素受体阳性早期乳腺癌患者保乳术后接受5年阿那曲唑或15次单纯放疗的疗效与成本效益。模型预测结果与现代临床试验一致:阿那曲唑在预防对侧乳腺癌上更优,放疗在预防同侧乳腺肿瘤复发上更优,其他4项肿瘤学终点无临床显著差异。生活质量调整生命年差异小,但放疗平均终生费用多3809美元,ICER提示阿那曲唑在62%概率模拟中具成本效益,但ICER因分母接近零而不稳定。

要点

  • 阿那曲唑预防对侧乳腺癌更优,放疗预防同侧乳腺肿瘤复发更优。
  • 其他4项肿瘤学终点无临床显著差异,生活质量调整生命年差异小。
  • 放疗平均终生费用多3809美元,ICER不稳定且阿那曲唑在62%模拟中具成本效益。

核心结论

  • 70岁以上低危早期乳腺癌患者若不愿或不能接受辅助阿那曲唑,可安全选择单纯辅助放疗,结局差异有限且费用适度增加。

研究设计与样本

  • 研究构建患者水平马尔可夫模型,比较5年阿那曲唑与15次无瘤床加量的单纯放疗。
  • 相对有效性基于NSABP B-21试验,并调整使单纯内分泌组匹配CALGB 9343和PRIME II试验。
  • 评估8项生存指标并与临床试验数据验证,同时考虑常见或严重副作用及成本效益。

主要发现

  • 模型预测结局与现代试验所示一致。
  • 阿那曲唑在预防对侧乳腺癌方面更优,对远处转移风险影响小。
  • 放疗在预防同侧乳腺肿瘤复发方面更优,对区域失败影响小。
  • 其他4项肿瘤学终点未见临床显著差异。
  • 生活质量调整生命年差异小,但放疗平均终生费用多3809美元。

关键数值与推荐

  • ICER提示阿那曲唑在62%的概率模拟中具成本效益。
  • ICER因分母接近零而不稳定。

临床怎么用

  • 对70岁以上低危早期乳腺癌且不愿或不能接受辅助阿那曲唑者,可考虑单纯辅助放疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hormone therapy without radiation therapy is considered appropriate for women age 70 or above with low-risk, hormone-positive breast cancer after partial mastectomy. However, some patients may prefer radiation without hormone therapy, for which there is minimal modern data. We modeled the comparative efficacy of aromatase inhibition alone without radiation versus radiation alone without hormone therapy. METHODS AND MATERIALS: We constructed a patient-level Markov model and compared 5 years of anastrozole to a 15-fraction course of radiation without boost or anastrozole. The relative effectiveness between treatments was based on the National Surgical Adjuvant Breast and Bowel Project B-21 trial, which was further adjusted such that the endocrine-alone arm matched the Cancer and Leukemia Group B 9343 and PRIME II trials. Common or severe side effects were considered. Eight survival metrics were assessed and validated against clinical trial data. The cost-efficacy of each strategy was considered using the quality-adjusted life year and incremental cost-effectiveness ratio (ICER). RESULTS: The model's predicted outcomes matched those demonstrated by modern trials. Aromatase inhibitors were superior in preventing contralateral cancers, with a small impact on the risk of distant metastatic disease. Radiation was superior in preventing ipsilateral breast tumor recurrence with a small impact on regional failure. No clinically significant differences were seen in the other 4 oncologic endpoints. Differences in quality-adjusted life years were small, but radiation therapy was $3809 more expensive over the average lifetime. The ICER suggested anastrozole was cost-effective in 62% of probabilistic simulations. However, the ICER was unstable owing to a denominator that approached zero. CONCLUSIONS: Women age 70 or above with low-risk early breast cancer who are reluctant or unable to pursue adjuvant aromatase inhibition can safely pursue adjuvant radiation alone with limited differences in outcome and a modest increase in costs.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ward MC, Vicini F, Chadha M, et al. Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation. Int J Radiat Oncol Biol Phys. 2019. PMID: 31212043. doi:10.1016/j.ijrobp.2019.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。